Bildcollage aus freien Fotos auf Pixabay

H5N1/Vogelgrippe seit 1997: Der Ever­green unter den Methoden, Panik zu ver­breiten [Neues von der WHO]

Was denken Sie, seit wann H5N1 als “Gefahr”, auf­grund einer poten­ti­ellen Pan­demie, für Men­schen weltweit auf­gebaut wird?

Nun, auf­ge­taucht ist das Virus 1997 in Hong Kong.

Der übliche Mas­senmord an Vögeln soll der ver­meint­lichen Gefahr für Men­schen ein Ende bereitet haben. Indes, das Potential von H5N1, als Methode, Men­schen Angst zu machen, wurde schnell erkannt, denn im Mai 1997 erkrankten 18 Per­sonen in Hong Kong an H5N1 und 6 davon sind ver­storben. Daraus, aus 18 Infek­tionen und sechs Toten hat nicht zuletzt die EU geschlossen, dass “an influenza pan­demic could be imminent“, weshalb Regie­rungen der Mit­glieds­staaten der EU mit vor­beu­genden Maß­nahmen reagiert haben. Indes, den vor­beu­genden Maß­nahmen ging ein Treffen, einer so gen­n­anten ad-hoc-Gruppe zu über­trag­baren Krank­heiten am 14. Januar 1998 voraus, initiiert vom DGV, der Direction General 5 der Euro­päi­schen Kommission.

Schon Anfang 1998 wurde die Sorge, viel­leicht auch Hoffnung, immerhin lässt sich mit H5N1 viel Geld ver­dienen, die Sorge dass H5N1 zur Pan­demie werden könnte, aus­giebig aus­ge­breitet und die Teil­nehmer der ad-hoc-Gruppe haben zu ihrem Schrecken fest­ge­stellt, dass es keine Impf­stoffe gegen das gerade erst gefundene Virus H5N1 gibt. Wie gewöhnlich, so hat auch diese Fest­stellung dazu geführt, dass Mil­lionen Euro aus Steu­er­geldern in die Erfor­schung eines Impf­stoffes gegen H5N1 geflossen sind.

Ein lukra­tives Geschäft.
Bester Beleg dafür ist die Anzahl der Impf­stoffe gegen H5N1, an denen derzeit geforscht wird.
Am besten Sie scrollen drüber:

NCT Number Study Title Sponsor
NCT03038776 Recom­binant H7 Hem­ag­glu­tinin Influenza Vaccine Trial Vaxine Pty Ltd
NCT00530660 Safety and Immu­no­ge­nicity Study of a Booster Vac­ci­nation With a Non-Adju­vanted H5N1 Influenza Vaccine (Follow Up to Study 810501) Ology Bio­ser­vices
NCT02743676 A Retro­s­pective, Obser­va­tional Registry of Par­ti­ci­pants With Avian Influenza Infection Hoffmann-La Roche
NCT04669691 A Dose-ranging Pediatric Study of an Adju­vanted Pan­demic Influenza Vaccine Seqirus
NCT03651544 The Study of the Safety, Reac­to­ge­nicity and Immu­no­ge­nicity of the GamFluVac Gam­aleya Research Institute of Epi­de­miology and Micro­biology, Health Ministry of the Russian Federation
NCT01142362 Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Elec­tro­po­ration in Healthy Adults Inovio Phar­maceu­ticals
NCT01107262 Avian Influenza Studies In Lebanon St. Jude Children’s Research Hospital
NCT00311480 Safety and Immu­no­ge­nicity of Two Doses, Admi­nis­tered Three Weeks Apart, of Two(Surface Antigen Adju­vanted With MF59C.1) Influenza Vac­cines in Non-Elderly Adult and Elderly Subjects Nov­artis
NCT01258062 Study to Assess Safety of an Inac­ti­vated H5N1 Influenza Vaccine Admi­nis­tered in GelVac Nasal Powder to Healthy Young Adults Ology Bio­ser­vices
NCT00417560 Inac­ti­vated Influenza A/H5N1 Vaccine in Adult Sub­jects at Risk of Occu­pa­tional Exposure to Live H5N1 Viruses Centers for Disease Control and Prevention
NCT03834376 Pre-Approval Access to Pimo­divir for the Tre­atment of Patients With H7N9 Influenza A Infection Janssen Research & Deve­lo­pment, LLC
NCT03472976 H5N1 With or Without Topical Aldara in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01184976 Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Elec­tro­po­ration Device In Healthy Adult Males GeneOne Life Science, Inc.
NCT00900991 Safety and Immu­no­ge­nicity of a Split-Virion Pan­demic Influenza A (H5N1) Vaccine in Children Sinovac Biotech Co., Ltd
NCT01698060 Immu­no­ge­nicity of ND1.1 by Delivery Directly to the Ileum Vaxart
NCT03755427 A Study of An Adju­vanted Inac­ti­vated H7N9 Influenza Vaccine Shanghai Institute Of Bio­lo­gical Products
NCT00489931 Phase I Open-Label Study of Recom­binant DNA Plasmid Vaccine, VRC-AVID­NA036-00-VP, Encoding for Influenza Virus H5 Hem­ag­glu­tinin Protein Given Intradermally National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00884182 Safety and Immu­no­ge­nicity of an Intra­mus­cular A/H5N1 Inac­ti­vated, Split Virion Pan­demic Influenza Vaccine in Children Sanofi Pasteur, a Sanofi Company
NCT00841763 Safety, Tole­r­a­bility and Immu­no­ge­nicity of Two Doses of Adju­vanted Mon­o­valent Influenza Vaccine Admi­nis­tered to Healthy Adult and Elderly Subjects Nov­artis
NCT02078674 A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant Novavax
NCT00783926 Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant) Ology Bio­ser­vices
NCT00640874 A Pro­s­pective Study to Examine the Effec­ti­veness and Safety of Anti­virals in Vol­un­teers Who Receive Short-term Pro­phy­laxis Against Pan­demic Influenza Kirby Institute
NCT03682120 Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59® Adjuvant to Prevent Avian Influenza National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01594320 A/H5N1 Virus-Like Par­ticle Antigen Dose Ranging Study With Adjuvant 1 Novavax
NCT03745274 Two Doses of GHB04L1 for Pan­demic Influenza Pro­phy­laxis in Healthy Adults AVIR Green Hills Bio­tech­nology AG
NCT00439530 Phar­ma­co­logic Study of Osel­ta­mivir in Healthy Volunteers Mahidol Uni­versity
NCT02839330 A Study to Eva­luate Safety, Immu­no­ge­nicity, and Lot-to-Lot Con­sis­tency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Sub­jects ≥18 Years of Age Seqirus
NCT00337896 T and B Cell Response to Avian Flu Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00439335 Higher Dose Intradermal H5 Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00516035 Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00478816 Safety and Immu­no­ge­nicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adju­vanted or Non-adju­vanted Influenza Vaccines Nov­artis Vaccines
NCT00537524 Immu­no­ge­nicity, Safety and Tole­r­a­bility of Two Doses of a Pre-pan­demic Influenza Vaccine in Par­ti­ci­pants Aged 6 Months to 17 Years Nov­artis Vaccines
NCT01044095 Study of Sea­sonal Influenza Vaccine Against H5N1 Avian Influenza Virus Armed Forces Research Institute of Medical Sci­ences, Thailand
NCT01995695 Safety and Immu­no­ge­nicity of a Live Atte­nuated H7N9 Influenza Virus Vaccine in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00347672 Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00545701 Immu­no­ge­nicity and Safety of an Intra­mus­cular A/H5N1 Inac­ti­vated, Split Virion Pan­demic Influenza Vaccine in Adults Sanofi Pasteur, a Sanofi Company
NCT01897701 A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 Novavax
NCT00519389 Safety, Reac­to­ge­nicity and Immu­no­ge­nicity of an H5N1 VLP Novavax
NCT02586792 H7N9 Boost in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02095444 Using Human Mens­trual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection S‑Evans Bio­sci­ences Co., Ltd.
NCT01323946 Study to Eva­luate the Immu­no­ge­nicity and Safety of an Inves­ti­ga­tional Pan­demic Influenza Vaccine in Children Gla­x­oS­mit­h­Kline
NCT00695669 A Trial to Test the Response to Dif­ferent Vac­ci­nation Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18–64 Gla­x­oS­mit­h­Kline
NCT00848029 Safety and Immu­no­ge­nicity of Two Doses of Mon­o­valent Inac­ti­vated Influenza Vaccine That is Adju­vanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pan­demic Virus Strain Can­didate (H5N1) in Adult and Elderly Sub­jects Using Four Dif­ferent Vac­ci­nation Schedules Nov­artis Vaccines
NCT00415129 Safety and Immu­no­ge­nicity of an Intra­mus­cular Pan­demic Influenza Vaccine in Adults and the Elderly Sanofi Pasteur, a Sanofi Company
NCT01382329 H5N1 Vaccine Study in Japanese Adults Ology Bio­ser­vices
NCT00841646 Safety and Immu­no­ge­nicity of Two Doses of Mon­o­valent Inac­ti­vated Influenza Vaccine That is Adju­vanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pan­demic Virus Strain Can­didate (H5N1) in Adult and Elderly Subjects Nov­artis Vaccines
NCT01573312 H5N1 Vac­ci­nation With and Without AS03: Systems Biology Analysis National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00382980 Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Alu­minum in Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00488046 Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00680069 H5N1 (Clade 2) Vac­ci­nation of Adults and Elderly National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00240968 H5 Booster After a Two Dose Schedule National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01640691 Immu­no­ge­nicity and Safety of Pan­demic Influenza Vaccine in Healthy Adults Adimmune Cor­po­ration
NCT01236040 Immu­no­ge­nicity and Safety of Pan­demic Influenza Vac­cines in Adults Aged 18 – 49 Years Old Gla­x­oS­mit­h­Kline
NCT02719743 A Dose Ranging Safety and Immu­no­ge­nicity Study of Gla­x­oS­mit­h­Kline (GSK) Bio­lo­gicals’ GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age Gla­x­oS­mit­h­Kline
NCT00719043 Immu­no­ge­nicity & Safety of GSK’s Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years Gla­x­oS­mit­h­Kline
NCT03739229 Reac­to­ge­nicity, Safety and Immu­no­ge­nicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine Research Institute of Influenza, Russia
NCT01657929 H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers Access to Advanced Health Institute (AAHI)
NCT00532792 A/H5N1 Dose Ranging Study With Adjuvant Patch Intercell USA, Inc.
NCT00895544 Immu­no­ge­nicity and Safety Study of a Single Prime-Boost Vac­ci­nation Schedule With a H5N1 Influenza Vaccine in Adults Ology Bio­ser­vices
NCT01942265 H7N9 Mix and Match With AS03 and MF59 in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02480101 Reac­to­ge­nicity, Safety and Immu­no­ge­nicity of a LAIV H7N9 Influenza Vaccine Research Institute of Influenza, Russia
NCT01147068 Safety and Immu­no­ge­nicity of PanBlok Influenza Vaccine in Healthy Adults Protein Sci­ences Corporation
NCT01766921 Safety and Immu­no­ge­nicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects Nov­artis Vaccines
NCT02151344 Eva­luating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Fol­lowed by an Inac­ti­vated H7N9 Influenza Virus Vaccine, Given at Varying Intervals National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT03312231 Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00311727 Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01086657 An Open-Label, Ran­do­mized Phase I Study in Healthy Adults of the Safety and Immu­no­ge­nicity of Prime-Boost Intervals With Mon­o­valent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Admi­nis­tered Alone or Fol­lowing Re… National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT03581903 A Study in Healthy Adults to Assess Priming With Anti­ge­ni­cally Mis­matched Live Atte­nuated A/H7N3 Influenza Virus Vaccine Fol­lowed by Inac­ti­vated A/H7N9 Influenza Virus Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00519064 Immu­no­ge­nicity and Safety of an Adju­vanted Inac­ti­vated Subunit Influenza Vaccine to Those of a Non-adju­vanted Inac­ti­vated Subunit Influenza Vaccine, When Admi­nis­tered to Adults Affected by Chronic Diseases Nov­artis Vaccines
NCT02206464 H7 Influenza Prime-Boost Regimens in Healthy Adults: Recom­binant H7 DNA Plasmid Vaccine, VRC-FLUD­NA071-00-VP, Admi­nis­tered Alone or With Mon­o­valent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Com­pared to MIV Prime With MIV Boo… National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT03369808 A Cli­nical Trail Of An Adju­vanted Inac­ti­vated H7N9 Influenza Vaccine Shanghai Institute Of Bio­lo­gical Products
NCT01195038 Immu­no­ge­nicity and Safety Study of a Booster Vac­ci­nation With a Recom­binant H5N1 Influenza HA Vaccine in Primed Adults UMN Pharma Inc.
NCT00561184 Safety and Immu­no­ge­nicity of a Booster Dose of ‑H5N1 Influenza Vaccine Nov­artis Vaccines
NCT01675284 A Phase I Study to Eva­luate the Safety, Reac­to­ge­nicity, and Humoral Immune Responses to an Inac­ti­vated H5N1 Influenza Vaccine Medigen Bio­tech­nology Corporation
NCT00640302 A Pro­s­pective Study to Examine the Effec­ti­veness and Safety of Neu­r­a­mi­nidase Inhi­bitors in Index Cases With Pre­sumed Pan­demic Influenza Kirby Institute
NCT02680002 Assess the Safety & Immu­no­ge­nicity of Stored Inac­ti­vated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant Bio­me­dical Advanced Research and Deve­lo­pment Authority
NCT01052402 Safety and Immu­no­ge­nicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents Ology Bio­ser­vices
NCT00110279 Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A) National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02091908 Safety and Immu­no­ge­nicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Sub­jects With and Without Under­lying Medical Conditions Seqirus
NCT00230750 Inac­ti­vated Influenza A/H5N1 Vaccine in the Elderly National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00853255 Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01403155 A Follow-On Study With an H5 Influenza Vaccine for Sub­jects Who Par­ti­ci­pated in Study FLU-001 Inovio Phar­maceu­ticals
NCT00297050 Safety and Dose Study of Pera­mivir for Influenza Treatment National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT03345043 Safety, Tole­r­a­bility, and Immu­no­ge­nicity of VAL-339851 in Healthy Adult Subjects ModernaTX, Inc.
NCT00755703 Safety and Immu­no­ge­nicity Study of Ade­no­virus-vec­tored, Intra­nasal Pan­demic Influenza Vaccine. Altimmune, Inc.
NCT01045564 Safety and Immu­no­ge­nicity of Vaccine in Adults at Occu­pa­tional Risk for Influenza A (H5N1) Exposure Gla­x­oS­mit­h­Kline
NCT00240903 Rev­ac­ci­nation With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02335164 A Phase 1 Study to Eva­luate the Immu­no­ge­nicity and Safety of a Pan­demic Avian Influenza Vaccine in Adults Vaxine Pty Ltd
NCT03014310 H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00711295 Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Spe­cified Risk Groups Ology Bio­ser­vices
NCT01250795 Safety and Immu­no­ge­nicity Of A Recom­binant H5N1 Vaccine In Adults Fraun­hofer, Center for Mole­cular Biotechnology
NCT01928472 Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years Nov­artis Vaccines
NCT00908687 A/H5N1/LT Dose Ranging Study Intercell USA, Inc.
NCT00298233 High-Dose Versus Standard-Dose Osel­ta­mivir to Treat Severe Influenza and Avian Influenza National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00434733 Immu­no­ge­nicity, Safety and Tole­r­a­bility of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects Nov­artis
NCT00382187 Safety and Immu­no­ge­nicity of Two Adju­vanted and One Non-adju­vanted H5N1 Influenza Vaccine in Adults Nov­artis Vaccines
NCT00280033 H5 Adult – Chiron Study of Bird Flu Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00660257 Safety and Immu­no­ge­nicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pan­demic Influenza(H5N1)Vaccine Sinovac Biotech Co., Ltd
NCT01086566 Cel­lular and Humoral Immune Response to Primary and Secondary Immu­nization With Sub­virion H5N1 Vaccines National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT05422326 A Study to Eva­luate Safety and Immu­no­ge­nicity of One or Two Booster Vac­ci­na­tions With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed Seqirus
NCT00868218 Study of a Par­en­te­rally Admi­nis­tered H5N1 Influenza Vaccine in Healthy Adults Rebecca Cox
NCT01074736 Host Genetic Sus­cep­ti­bility to Avian Influenza A/H5N1 South East Asia Infec­tious Disease Cli­nical Research Network
NCT02295813 Safety and Phar­ma­co­ki­netics Study of FBF001 Fab’entech
NCT00694213 Pan­demic Influenza Plasmid DNA Vac­cines (Needle-Free) Vical
NCT00311649 Open Label Eva­luation of H5N1 Vaccine at Vaccine Manu­fac­turing Facilities National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01999842 Immu­no­ge­nicity and Safety Study of Gla­x­oS­mit­h­Kline (GSK) Bio­lo­gicals’ Influenza Vaccine(s) GSK3206641A and GSK3206640A Admi­nis­tered in Adults 18 to 64 Years of Age Gla­x­oS­mit­h­Kline
NCT01938742 H7N9 Mix and Match With MF59 in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01443936 Expe­ri­mental AD4-H5-VTN Vaccine in Healthy Volunteers National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00402649 Open-Label Study of H5 Vaccine in Par­ti­ci­pants of Pro­tocol 04–077 National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02171819 Influenza A/H5N1 Vaccine Cli­nical Trial (IVACFLU‑A/H5N1) – Phase 1 Institute of Vac­cines and Medical Bio­lo­gicals, Vietnam
NCT01511419 Safety Trial of Live Atte­nuated Influenza (H7N3) Vaccine PATH
NCT00133536 A/H5N1 Vaccine in Healthy Children Aged 2–9 Years National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00310206 H5N1 Vaccine Intra­mus­cular Versus Intradermal in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00294099 H5 Vaccine Alone or With Alu­minum Hydr­oxide in Elderly Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00517517 Safety and Immu­no­ge­nicity Study of Two Doses of an Inac­ti­vated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) Ology Bio­ser­vices
NCT00296634 H5 Vaccine Alone or With Adjuvant in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02177734 Immu­no­ge­nicity and Safety Study of Gla­x­oS­mit­h­Kline (GSK) Bio­lo­gicals’ Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age Gla­x­oS­mit­h­Kline
NCT01353534 Open-label Study to Assess Immu­no­ge­nicity and Safety of a Vaccine Enhancement Patch When Admi­nis­tered With 2 Doses of H5N1 Vaccine Intercell USA, Inc.
NCT01317758 H5N1 Mix and Match With AS03 National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00912496 Booster Trial to 07–0019 With A/Anhui/05 With and Without MF59 National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01596725 A/H5N1 Virus-Like Par­ticle Antigen Dose Ranging Study With Adjuvant 2 Novavax
NCT02691130 Assess the Safety and Immu­no­ge­nicity of M‑001 as A Stan­dalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults BiondVax Phar­maceu­ticals ltd.
NCT02229357 Eva­luation of Priming Effects by PLAI Vaccine on the Sub­se­quent Response to Inac­ti­vated H5N1 Vaccine Mahidol Uni­versity
NCT01776541 Safety and Immu­no­ge­nicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults Nov­artis Vaccines
NCT01037634 Safety and Efficacy of Osel­ta­mivir in Children Younger Than One Year of Age National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01578317 Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00115986 A/H5N1in Adult – Aventis National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01443663 Eva­luating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Pre­viously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Atte­nuated Influenza Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00664417 Study of Dif­ferent For­mu­la­tions of an Intra­mus­cular A/H5N1 Inac­ti­vated, Split Virion Influenza Adju­vanted Vaccine Sanofi
NCT03738241 2017 A/H7N9 IIV Revaccination National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02624219 H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT03283319 Panblok H7 Vaccine Adju­vanted With AS03 or MF59 Bio­me­dical Advanced Research and Deve­lo­pment Authority
NCT00349141 Safety and Immu­no­ge­nicity Study of an Inac­ti­vated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) Ology Bio­ser­vices
NCT01310413 Mon­o­valent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Gla­x­oS­mit­h­Kline
NCT00812019 Dose Ranging Study to Eva­luate Immu­no­ge­nicity and Safety of Adju­vanted or Non-adju­vanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18–40 Years Old) Seqirus
NCT05397119 A Safety and Immu­no­ge­nicity of Intra­nasal Nano­emulsion Adju­vanted Recom­binant Pan­demic Flu Vaccine in Healthy Adults Blue­Willow Biologics
NCT01298206 Case-control Study of Pan­demic A/H1N1 Influenza Risk Factors In Lebanon St. Jude Children’s Research Hospital
NCT01389466 Study to Eva­luate the Safety and Immu­no­ge­nicity of MG1109 in Healthy Adult Volunteers Green Cross Corporation
NCT00481065 Immu­no­ge­nicity, Safety and Tole­r­a­bility of Pre­pan­demic Influenza and Sea­sonal Influenza Vaccine in Adult Subjects Nov­artis
NCT01379937 A Study to Eva­luate the Safety and Immu­no­ge­nicity of a Prime-boost Schedule of GSK Bio­lo­gicals’ Influenza Vaccine in Children Gla­x­oS­mit­h­Kline
NCT01910519 Systems Biology of Influenza A (H5N1) Virus Mon­o­valent Vaccine With and Without Adjuvant System 03 (AS03) National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00814385 Immu­no­ge­nicity of Adju­vanted or Non-adju­vanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04 Uni­versity Hos­pitals, Leicester
NCT00491985 Safety and Immu­no­ge­nicity of 2 For­mu­la­tions of an Intra­mus­cular A/H5N1 Pan­demic Influenza Vaccine in Children Sanofi Pasteur, a Sanofi Company
NCT00408109 Safety Study of Avian Flu Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00771615 Immu­no­ge­nicity & Safety of GSK’s Avian Flu Vaccine 1557484A Given to Adults Aged 18–64 Years Gla­x­oS­mit­h­Kline
NCT01656356 Phase I Safety and Immu­no­ge­nicity of Live Atte­nuated Influenza H5 Can­didate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers Mahidol Uni­versity
NCT02612909 A Safety and Immu­no­ge­nicity Study of IVACFLU‑A/H5N1 Institute of Vac­cines and Medical Bio­lo­gicals, Vietnam
NCT02107807 Safety and Immu­no­ge­nicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Sub­jects With and Without Immu­no­sup­pressive Con­di­tions *aH5N1:Monovalent H5N1 Influenza Vaccine Seqirus
NCT00457509 Safety and Immu­no­ge­nicity of H5N1 Adju­vanted, Inac­ti­vated, Split-Virion Pan­demic Influenza Vaccine in Healthy Adults Sanofi Pasteur, a Sanofi Company
NCT00428753 China Case Control Avian Influenza National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00703053 H5N1 Priming and Boosting Strategies National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01317745 H5N1 Mix and Match With MF59 National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01676675 A Phase I Cli­nical Trial With Whole Virus Inac­ti­vated Influenza H5N1 Vaccine in Healthy Ado­le­s­cents and Adults Jiangsu Pro­vince Centers for Disease Control and Prevention
NCT00397215 Eva­luate Safety & Immu­no­ge­nicity of a Pan­demic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age Gla­x­oS­mit­h­Kline
NCT00620815 Safety and Immu­no­ge­nicity of Two Doses of a Tetra­valent Influenza Vaccine in Adults Aged 18 Years and Above Nov­artis Vaccines
NCT00462215 Phase 3 Immu­no­ge­nicity and Safety Study of an Inac­ti­vated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived) Ology Bio­ser­vices
NCT01774032 H5N1 Vaccine Study in Japanese Elderly Popu­lation Aged 65 Years and Older Ology Bio­ser­vices
NCT01150552 Studies of Avian Influenza Trans­mission to Humans in Egypt St. Jude Children’s Research Hospital
NCT00709800 Pan­demic Influenza Plasmid DNA Vac­cines (Needle) Vical
NCT01658800 Study of the Safety and Immu­no­ge­nicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18–49 VaxInnate Cor­po­ration
NCT00734175 Safety of and Immune Response to Recom­binant Live-Atte­nuated Influenza H6N1 Virus Vaccine Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00311675 St. Jude Open Label H5 Trial National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00922259 Safety and Immu­no­ge­nicity of Live Influenza A Vaccine for Avian Influenza H7N7 National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT03318315 Co-Admi­nis­tration of AS03 Adju­vanted A/H7N9 IIV With IIV4 National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00380237 Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B) National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT03330899 Safety and Immu­no­gencity of H7N9 Influenza Antigen With 2 Adjuvant For­mu­la­tions in Healthy Adults in Brazil Butantan Institute
NCT03497845 Assess the Safety & Immu­no­ge­nicity of Prime-Boost Vac­ci­nation Stra­tegies Using H5Nx Virus Vaccine Adju­vanted With AS03 or MF59 Bio­me­dical Advanced Research and Deve­lo­pment Authority
NCT02274545 Eva­luating the Safety and Immu­no­ge­nicity of a H7N9 Vaccine for the Pre­vention of Influenza H7N9 Disease in Adults 50 to 70 Years Old National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01335347 Safety Study of an Oral Vaccine to Prevent Avian Influenza Vaxart
NCT00309647 Study to Eva­luate the Safety and Immu­no­ge­nicity of Pan­demic Mon­o­valent (H5N1) Influenza Vac­cines (Whole Virus For­mu­lation) in Adults 18 and 60 Years of Age Gla­x­oS­mit­h­Kline
NCT00980447 Immu­no­ge­nicity, Safety and Optimal Dose Finding Study of Recom­binant Influenza H5N1 Vaccine in Healthy Young Adults UMN Pharma Inc.
NCT00984945 Safety Study of a Plant-based H5 Virus-Like Par­ticles (VLP) Vaccine in Healthy Adults Medicago
NCT00356798 Ran­do­mized, Double Blinded, Placebo Control Cli­nical Trial of Pan­demic Influenza Inactive Vaccine on Healthy Subjects Sinovac Biotech Co., Ltd
NCT01006798 Safety and Immu­no­ge­nicity of Repli­cation-Com­petent Ade­no­virus 4‑vectored Vaccine for Avian Influenza H5N1 Emergent Bio­So­lu­tions
NCT00319098 Study to Eva­luate the Safety and Immu­no­ge­nicity of a Pan­demic Influenza Vaccine in Adults Aged 18 Years and Above Gla­x­oS­mit­h­Kline
NCT01416571 Immu­no­ge­nicity and Safety Study of Gla­x­oS­mit­h­Kline (GSK) Bio­lo­gicals’ Mon­o­valent Pan­demic H5N1 Vaccine in Adults Gla­x­oS­mit­h­Kline
NCT00428493 Pro­s­pective Study of AI H5N1 in China National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02957656 Safety and Immu­no­ge­nicity of Priming With Live Atte­nuated A/H7N9 Influenza Virus Vaccine Fol­lowed By Inac­ti­vated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02153671 Immu­no­ge­nicity of H5N1 Vaccine Fol­lowing H5N2 PATH
NCT00914771 Safety and Immu­no­ge­nicity of Two Doses, Admi­nis­tered Three Weeks Apart, of Two Mon­o­valent H5N1 Influenza Vac­cines Con­taining 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects Nov­artis Vaccines
NCT00383071 Deve­lo­pment of Immune Glo­bulin Tre­atment for Avian Flu National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01560793 Safety and Immu­no­ge­nicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18–49 Years VaxInnate Cor­po­ration
NCT01776554 Safety and Immu­no­ge­nicity of Two Doses of H5N1 Influenza Vaccine in Children Nov­artis Vaccines
NCT04789577 A Study to Eva­luate the Safety and Immu­no­ge­nicity of Gla­x­oS­mit­h­Kline Bio­lo­gicals’ Influenza Vaccine GSK3206641A Admi­nis­tered in Adults 18 to 64 Years of Age and 65 Years of Age and Older Gla­x­oS­mit­h­Kline
NCT02213354 H7N9 Mix and Match With MF59 in Healthy Elderly Persons National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT03701061 Dura­bility and Impact of the Sea­sonal Influenza Vaccine on H5 Induced B Cell Response Emory Uni­versity
NCT02436928 A Study to Eva­luate the Safety and Immu­no­ge­nicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects Medigen Vaccine Bio­logics Corp.
NCT03196661 Preli­minary Study on Safety and Immu­no­ge­nicity of Influenza A (H7N9) Vaccine in the Population Hualan Bio­lo­gical Bac­terin Co. Ltd.
NCT01788228 Safety and Tole­r­a­bility Study of Gla­x­oS­mit­h­Kline (GSK)1557484A Vaccine in Adults at Occu­pa­tional Risk for Influenza A (H5N1) Exposure Gla­x­oS­mit­h­Kline
NCT00640211 A Pro­s­pective Study to Examine the Effec­ti­veness and Safety of Neu­r­a­mi­nidase Inhi­bitors in Vol­un­teers Who Receive Long-term Pro­phy­laxis Against Pan­demic Influenza: PIPET B Kirby Institute
NCT03816878 Immu­no­ge­nicity and Safety Study of Inac­ti­vated Subunit H5N1 Influenza Vaccine in Prior Reci­pients of Live Atte­nuated H2N2, H6N1 and H9N2 Influenza Vac­cines and in H5N1 and Live Atte­nuated Vaccine Naïve Individuals National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00776711 Vaccine for Pre­vention of Bird Flu National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT03589807 2013/2017 H7N9 Prime-Boost Interval National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT02251288 A Phase I Study Priming With an Inac­ti­vated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Fol­lowed by Live Atte­nuated A/H7N9 Influenza Virus Vaccine National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT00900588 Safety and Immu­no­ge­nicity of a Split-Virion Pan­demic Influenza A (H5N1) Vaccine in Adolescents Sinovac Biotech Co., Ltd
NCT01987011 Phase III Study to Eva­luate the Immu­no­ge­nicity and Safety of MG1109 in Healthy Adult Volunteers Green Cross Corporation
NCT02921997 H7N9 Vac­ci­nation With and Without AS03 and Unad­ju­vanted H3N2v Vac­ci­nation: Standard and Systems Biology Analyses National Institute of Allergy and Infec­tious Diseases (NIAID)
NCT01911754 Japanese Pediatric H5N1 Vaccine Study Ology Bio­ser­vices

Da ist Geld drin…

Wenn so viele unter­schied­liche Phar­mafia-Unter­nehmen an ein und dem­selben “Impf­stoff” basteln, gegen ein Virus das sich nach wie vor standhaft weigert, von Mensch zu Mensch über­tragbar in rele­vantem Ausmaß zu sein, dann muss man kein Prophet sein, um zu wissen, dass die hier ver­sam­melten finan­zi­ellen Inter­essen einen Weg finden werden, ihre For­schung zu Mil­li­arden zu machen.

Indes, wie gesagt, es gibt da ein Problem.
Seit 1998 wird die Gefahr von H5N1/Vogelgrippe als Material, aus dem töd­liche Pan­demien sind, stetig beschworen, indes, H5N1 weigert sich standhaft.

Hier ein paar Bei­spiele der aka­de­mi­schen Panikmachen:

2004:
Guan, Y., L. L. M. Poon, C. Y. Cheung, T. M. Ellis, W. Lim, A. S. Lipatov, K. H. Chan et al. (2004). H5N1 influenza: a protean pan­demic threat. Pro­cee­dings of the National Academy of Sci­ences 101(21): 8156–8161.

Ergebnis: H5N1 wird anste­ckender und zu einer zuneh­menden Gefahr für Menschen
Anbindung der Autoren: Government Virus Unit, Department of Health, Peoples Republic of China;

Fer­guson, Neil M., Chris­tophe Fraser, Christl A. Don­nelly, Azra C. Ghani, and Roy M. Anderson. (2004). Public health risk from the avian H5N1 influenza epi­demic. Science 304(5673): 968–969.

Ergebnis: Die Leute um Neil Fer­guson, der Neil Fer­guson, der mit fal­schen Modellen 2020 ein Mas­sen­sterben an COVID-19 vor­her­gesagt hat, emp­fehlen in diesem Beitrag der WHO, die Gefahr, die von H5N1 ausgeht, nicht auf­grund der Fälle tat­sächlich infi­zierter Men­schen, sondern auf­grund der ver­bes­serten Fähigkeit des Virus zur Trans­mission zu beur­teilen. Also nicht auf­grund von Fakten, sondern auf­grund der Ergeb­nisse eines Simu­la­ti­ons­mo­dells. Kommt irgendwie bekannt vor…
Anbidung der Autoren: Imperial College, London;

Achtung For­schung:

Webster, Robert G., Malik Peiris, Honglin Chen, and Yi Guan (2006). H5N1 out­breaks and enzootic influenza.Bio­di­versity 7(1): 51–55.

Ergebnis: “In fact, the root cause of the con­ti­nuing H5N1 pan­demic threat may be the way the patho­ge­nicity of H5N1 viruses is masked by cocir­cu­lating influenza viruses or bad agri­cul­tural vaccines.”

Dass H5N1 unter Geflügel regel­mäßig auf­tritt, ist nach Ansicht der Autoren u.a. ein Hinweis auf schlechte Impf­stoffe, die in der Tier­haltung zum Einsatz kommen. Ein bekanntes Thema …

Anbindung: St Jude Childrens Hos­pital Fort Lau­derdale und Uni­versity of Hong Kong

2007:

Peiris, JS Malik, Menno D. De Jong, and Yi Guan (2007). Avian influenza virus (H5N1): a threat to human health. Cli­nical micro­biology reviews 20(2): 243–267.

Ergebnis: Natürlich ist H5N1 eine Gefahr für Menschen.
Anbindung der Autoren: Uni­versity of Hong Kong, Oxford University

2011:

Amendola, A., A. Rang­hiero, A. Zanetti, and E. Pariani (2011). “Is avian influenza virus A (H5N1) a real threat to human health. Journal of Pre­ventive Medicine and Hygiene 52(3): 107–110.

Ergebnis: Derzeit ist H5N1 keine Gefahr, aber wenn es H5N1 geling, von Mensch zu Mensch über­tragbar zu sein, dann schon.
Anbindung der Autoren: Uni­versity of Milan

2012:

To, Kelvin KW, Kenneth HL Ng, Tak-Lun Que, Jacky MC Chan, Kay-Yan Tsang, Alan KL Tsang, Honglin Chen, and Kwok-Yung Yuen (2012). “Avian influenza A H5N1 virus: a con­ti­nuous threat to humans. Emerging microbes & infec­tions 1(1): 1–12.

Ergebnis: Das Virus ent­wi­ckelt sich schnell (ist ja auch ein RNA-Virus) und stellt ein kon­ti­nu­ier­liches Risiko für eine Pan­demie für Men­schen dar.
Anbindung der Autoren: Princess Mar­garet Hos­pital, Hong Kong, Uni­versity of Hong Kong

2013

Van Kerkhove, Maria D. (2013). Brief lite­rature review for the WHO global influenza research agenda–highly patho­genic avian influenza H5N1 risk in humans. Influenza and other respi­ratory viruses 7: 26–33.

Ergebnis: Anste­ckung nur bei extrem hoher Virenlast für Men­schen möglich, keine Indizien für Mensch-zu-Mensch Über­trag­barkeit des Virus, aber natürlich ganz große Gefahr…

Anbindung: Imperial College, London

Beenden wir den Über­blick an dieser Stelle, schon weil nach 2013 so gut wie keine Bei­träge mehr zu finden sind, die sich mit dem Risiko einer Mensch-zu-Mensch-Über­tragung von H5N1 befassen. Warum dem so ist, dazu mag die fol­gende Tabelle einen Erklä­rungs­beitrag leisten:

WHO

Abge­sehen von einem kurzen Aus­bruch in Ägypten spielt H5N1 im viralen Geschehen der Welt nach 2014 keine Rolle mehr und die Tat­sache, dass For­schung den Ver­dacht nahe­gelegt hat, der Mas­sen­einsatz von Impf­stoffen gegen H5N1 in der Tier­haltung trage seinen Teil dazu bei, H5N1 virulent und ende­misch zu halten, mag auch als Dämpfer für all die­je­nigen gewirkt haben, die mit ihren For­schungs­er­geb­nissen lieber nicht Gefahr laufen, ihre Finan­zierung durch die Phar­mafia zu verlieren.

Ergo wurde es ruhig um H5N1, so ruhig, dass sich die WHO-Mannen heute redlich mühen müssen, die Angst vor H5N1 künstlich zu schüren und wieder ans Laufen zu bringen:

Sie sehen gerade einen Platz­hal­ter­inhalt von Standard. Um auf den eigent­lichen Inhalt zuzu­greifen, klicken Sie auf den Button unten. Bitte beachten Sie, dass dabei Daten an Dritt­an­bieter wei­ter­ge­geben werden.

Weitere Infor­ma­tionen

Sie sehen gerade einen Platz­hal­ter­inhalt von Standard. Um auf den eigent­lichen Inhalt zuzu­greifen, klicken Sie auf den Button unten. Bitte beachten Sie, dass dabei Daten an Dritt­an­bieter wei­ter­ge­geben werden.

Weitere Infor­ma­tionen

Dr Tedros und Jeremy Farrar, gestern noch aktiv an der Ver­tu­schung der Her­kunft von SARS-CoV‑2 beteiligt, heute der Chief Medical Adviser bei der WHO, ver­mutlich zur Belohnung, mühen sich redlich, die in Daten nicht belegbare Gefahr, die von H5N1 ausgeht, zu beschwörden und die Geld­ma­schine für Phar­mafia-Unter­nehmen am Laufen zu halten. Die Stra­tegie hat sich in all den Jahren, die H5N1 nun schon beschworen wird, nie geändert.

H5N1 sei derzeit nicht von Mensch-zu-Mensch zu über­tragen, so, Farrar, aber dennoch gefährlich, weil die Gefahr bestehe, dass es in Zukunft von Mensch-zu-Mensch über­tragbar sein könnte. Eine Aussage, die auf nahezu jedes Virus zutrifft. Indes, H5N1 wurde in den letzten Jahren so pro­minent auf­gebaut und wohl mit Hilfe von “Impf­stoffen” virulent unter Tieren gehalten (Webster et al. 2006), dass es derzeit keine Angst-Alter­native zu H5N1 gibt. Also müssen die Angst-Agi­ta­toren mit dem arbeiten, was sie haben. Herzlich wenig, wenn man die Tabelle mit den kumu­la­tiven Fällen von H5N1 unter Men­schen betrachtet.

Deshalb wird derzeit gemolken, was geht, und Farrar gibt sich im letzten Video alle Mühe, das, was er nicht weiß, nicht etwa als Unwissen, sondern als Gefahr aus­zu­geben, was, ange­sichts der Gefahr, dass uns der Himmel auf den Kopf fallen könnte, auf besonders ängst­liche Naturen seine Wirkung nicht ver­fehlen dürfte. Er hat keine Ahnung, wie die Über­tragung von Kühen zu Men­schen, Tieren statt­findet, ob sie statt­findet, aber natürlich ist sie eine große Gefahr, was ange­sichts der Tat­sache, dass Farrar kei­nerlei Daten hat, um die Gefahr zu quan­ti­fi­zieren, seltsam ist. Wenn man nichts weiß, wie kann man dann wissen, dass von dem, von dem man nichts weiß, eine große Gefahr ausgeht?

Wie auch immer.
Das ganze der­zeitige Tohu­wabohu basiert auf H5N1 unter Rindern und einem Farm­ar­beiter, der an H5N1 erkrankt ist. Indes, betrachtet man dessen “Krank­heits­ge­schichte” etwas genauer, dann reibt man sich ver­wundert die Augen:

Ende März 2024 klagte ein Farm­ar­beiter über Rötung und Unwohlsein am rechten Auge. Fest­ge­stellt wurde eine sub­kon­junk­tivale Blutung und eine dünne, seröse Drainage. Ansonsten nichts. Normale Atmung, klare Lunge, kein Fieber, keine respi­ra­to­ri­schen Sym­ptome, nichts. Der Farm­ar­beiter hatte kei­nerlei Kontakt zu toten oder kranken Vögeln, aber mit gesunden und kranken Milch­kühen, die eben­falls gerötete Augen hatten, weniger Milch gaben, weniger Appetit auf­wiesen und zuweilen eine erhöhte Tem­pe­ratur hatten. Er trage Hand­schuhe, aber keinen Atem- oder Augen­schutz bei der Arbeit mit Kühen. Ein PCR-Test war positiv für H5-Viren, die Sym­ptome des Arbeiters ver­schwanden nach einer Behandlung mit Osel­ta­mivir. Eine Analyse der Gen­se­quenz des H5N1-Virus, das bei Arbeiter und Kühen fest­ge­stellt wurde, zeigte kei­nerlei Fähigkeit, an mensch­liche Zellen anzubinden:

“Viral sequences from cattle and from the worker main­tained pri­marily avian genetic cha­rac­te­ristics and lacked changes in the hem­ag­glu­tinin gene that would affect receptor-binding spe­ci­ficity (e.g., binding to α2–6–linked sialic acid receptors, pri­marily located in the human upper respi­ratory tract) and trans­mission risk to humans.”

Uyeki, Timothy M., Scott Milton, Che­rissa Abdul Hamid, Cynthia Reinoso Webb, Steven M. Presley, Varun Shetty, Susan N. Rollo et al. (2024). Highly Patho­genic Avian Influenza A (H5N1) Virus Infection in a Dairy Farm Worker. New England Journal of Medicine.

Kurz: Wir sind immer noch da, wo wir 1997 waren, als H5N1 ent­deckt wurde.

Kei­nerlei Hinweis darauf, dass H5N1 die Fähigkeit erlangen könnte, von Mensch-zu-Mensch über­tragbar zu sein. Indes, es ist natürlich schon seit Jahren von Mensch zu Mensch über­tragbar. Beim ersten Aus­bruch von H5N1 in Hong Kong reiste die Mutter einer Infi­zierten an, um die Kranke zu pflegen. Sie infi­zierte sich mit H5N1 und ver­starb. Indes legen Studien nahe, dass die Viren­ladung, die benötigt wird, um H5N1 von Mensch zu Mensch zu über­tragen, so groß ist, dass man stun­denlang dem Virus aus­ge­setzt sein muss, um über­haupt eine Wahr­schein­lichkeit auf Anste­ckung und Erkrankung zu haben (van Kerkhove 2014).

Aber selbst dann, wenn man die Daten, die oben in der WHO-Tabelle abge­bildet sind, zur Grundlage nimmt, um die Über­trag­barkeit von H5N1 sta­tis­tisch zu quan­ti­fi­zieren, erzielt man Ergeb­nisse, die die Gefahr, die mit dem Virus ver­bunden sein soll, etwas rela­ti­vieren. So finden Yang-Yang et al. (2007) kei­nerlei sta­tis­tische Belege dafür, dass ein Aus­bruch in der Türkei durch Über­tragung von Mensch-zu-Mensch ver­ur­sacht wurde und die sta­tis­ti­schen Belege, die sie für einen Aus­bruch in Sumatra gefunden zu haben glauben, sind Junk, denn sie ver­letzten die Parität mit einem Wer­te­be­reich von 0,61 bis 2,14:

“We find sta­tis­tical evi­dence of human-to-human trans­mission (p = 0.009) in Sumatra but not in Turkey (p = 0.114). For Sumatra, the esti­mated household SAR was 29% (95% con­fi­dence interval [CI] 15%–51%). The esti­mated lower limit on the local R0 was 1.14 (95% CI 0.61–2.14).”

Yang, Yang, M. Elizabeth Halloran, Jonathan D. Sug­imoto, and Ira M. Longini Jr. (2007). Detecting human-to-human trans­mission of avian influenza A (H5N1). Emerging infec­tious diseases 13(9): 1348.

Es gibt kei­nerlei Anhalts­punkt dafür, dass von H5N1 derzeit und in abseh­barer Zeit eine Gefahr für Men­schen ausgeht oder aus­gehen wird. Alles, was dazu in den Medien berichtet und von inter­es­sierten Kreisen ver­breitet wird, dient der Panik­mache, der Vor­be­reitung einer men­schen­ge­machten Pan­demie, die als zoo­no­tische H5N1-Pan­demie aus­ge­geben werden wird oder dem Zweck, die Legi­ti­mation dafür zu schaffen, Mil­li­arden Steu­er­gelder in den Koffern von Phar­mafia-Unter­nehmen zu vergraben.

Der Artikel erschien zuerst bei ScienceFiles.org.

  • Top Artikel

  • Service-Hotline:
    0179-6695802

  • Servicezeiten:
    Mo. und Do.: 10:00 - 12:00 Uhr
    Mi.: 15:00 - 18:00 Uhr